Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Normotensive male or female volunteers, with a body mass index of 18.0-30.0 kg/m2.~* Deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine.~* Agree to follow the contraception requirements of the trial.~* Able to give fully informed written consent.~* Agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication.~Exclusion Criteria:~* History or presence of iron deficiency or iron deficiency anaemia and/or currently receiving oral or parenteral iron supplementation as treatment for those conditions.~* Positive tests for hepatitis B \& C, HIV~* Drug or alcohol abuse.~* Smoke more than 10 cigarettes (or equivalent) daily.~* Use of over-the-counter medication (with the exception of paracetamol \[acetaminophen\]) during the 7 days before the first dose of trial medication, or prescribed medication (with the exception of hormone replacement therapy \[HRT\]) during the 28 days before first dose of trial medication.~* Use of supplement(s) during the 28 days before screening.~* Participation in other clinical trials of unlicensed medicines, or loss of more than 400 mL blood, within the previous 3 months.~* Clinically relevant abnormal medical history or concurrent medical condition.~* Pre-menopausal females who are pregnant or lactating, or who are sexually active and not using a reliable method of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 1.0mg/kg (Type: EXPERIMENTAL): Drug: SLN124
- Placebo (Type: PLACEBO_COMPARATOR): None
- 3.0mg/kg (Type: EXPERIMENTAL): Drug: SLN124
- Optional Cohort (Type: EXPERIMENTAL): An additional dose level may be explored

Based on this trial design, predict the completion outcome and termination type (if applicable).